| 1. |
- Doak, Daniel F., et al.
(författare)
-
Recommendations for Improving Recovery Criteria under the US Endangered Species Act
- 2015
-
Ingår i: BioScience. - : Oxford University Press (OUP). - 0006-3568 .- 1525-3244. ; 65:2, s. 189-199
-
Tidskriftsartikel (refereegranskat)abstract
- Recovery criteria, the thresholds mandated by the Endangered Species Act that define when species may be considered for downlisting or removal from the endangered species list, are a key component of conservation planning in the United States. We recommend improvements in the definition and scientific justification of recovery criteria, addressing both data-rich and data-poor situations. We emphasize the distinction between recovery actions and recovery criteria and recommend the use of quantitative population analyses to measure the impacts of threats and to explicitly tie recovery criteria to population status. To this end, we provide a brief tutorial on the legal and practical requirements and constraints of recovery criteria development. We conclude by contrasting our recommendations with other alternatives and by describing ways in which academic scientists can contribute productively to the planning process and to endangered species recovery.
|
|
| 2. |
- Rogers, Kathleen E., et al.
(författare)
-
Novel Cruzain Inhibitors for the Treatment of Chagas' Disease
- 2012
-
Ingår i: Chemical Biology and Drug Design. - : Wiley. - 1747-0277 .- 1747-0285. ; 80:3, s. 398-405
-
Tidskriftsartikel (refereegranskat)abstract
- The protozoan parasite Trypanosoma cruzi, the etiological agent of Chagas disease, affects millions of individuals and continues to be an important global health concern. The poor efficacy and unfavorable side effects of current treatments necessitate novel therapeutics. Cruzain, the major cysteine protease of T.similar to cruzi, is one potential novel target. Recent advances in a class of vinyl sulfone inhibitors are encouraging; however, as most potential therapeutics fail in clinical trials and both disease progression and resistance call for combination therapy with several drugs, the identification of additional classes of inhibitory molecules is essential. Using an exhaustive virtual-screening and experimental validation approach, we identify several additional small-molecule cruzain inhibitors. Further optimization of these chemical scaffolds could lead to the development of novel drugs useful in the treatment of Chagas disease.
|
|
